<DOC>
	<DOCNO>NCT01102244</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy safety Tobradex ST compare AzaSite treatment moderate severe chronic blepharitis .</brief_summary>
	<brief_title>A Study Evaluate Clinical Efficacy Safety Tobradex® ST Compared Azasite® Treatment Subjects With Moderate Severe Chronic Blepharitis</brief_title>
	<detailed_description />
	<mesh_term>Blepharitis</mesh_term>
	<criteria>Have diagnosis moderate severe chronic blepharitis define minimum score least `` 1 '' one lid sign , one conjunctival sign , one symptom least one eye Have minimum global score ( total sign symptom score ) 5 eye qualifying . Have know sensitivity poor tolerance test article ( tobramycin , dexamethasone , azithromycin ) component therapy associate trial Have history ocular surgical intervention within six ( 6 ) week prior Visit 1 study Have ocular infection ( bacterial , viral fungal ) active ocular inflammation ( i.e . follicular conjunctivitis , iritis ) preauricular lymphadenopathy , blepharitis Have wear contact lenses 72 hour prior visit 1 duration study Are currently take medication know cause ocular dry stable dose least 30 day Have use topical ocular systemic antibiotic within 7 day enrollment . Stable ( great 1 month prior enrollment ) use topical antibiotic face ( except around eye ) dermatologic condition allow . Dose must continue unchanged duration study Have use topical ocular aerosolized/nebulized systemic corticosteroid agent within 14 day enrollment . Stable ( great 1 month prior enrollment ) use inhale ( use mouthpiece ) nasal corticosteroid topical dermal steroid ( except around eyelid ) allow . Dose must continue unchanged duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>blepharitis</keyword>
	<keyword>moderate severe chronic blepharitis</keyword>
</DOC>